About
Abscint develops anti-HER2 positron emission tomography (PET) tracers using single-domain antibodies to enable non-invasive, whole-body imaging diagnostics for HER2-positive cancers, facilitating precise disease evaluation and treatment monitoring.
Explore Abscint's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.